Bank of Montreal Can Grows Position in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Bank of Montreal Can lifted its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 43.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 21,640 shares of the company’s stock after purchasing an additional 6,570 shares during the quarter. Bank of Montreal Can owned about 0.29% of VanEck Pharmaceutical ETF worth $2,052,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of VanEck Pharmaceutical ETF by 51.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 248,473 shares of the company’s stock worth $23,565,000 after buying an additional 84,273 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of VanEck Pharmaceutical ETF by 33.6% during the third quarter. Thrivent Financial for Lutherans now owns 234,890 shares of the company’s stock worth $22,322,000 after purchasing an additional 59,025 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in VanEck Pharmaceutical ETF by 1.7% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 160,039 shares of the company’s stock valued at $14,641,000 after purchasing an additional 2,694 shares in the last quarter. Financial Partners Group Inc purchased a new stake in VanEck Pharmaceutical ETF during the 2nd quarter worth $8,701,000. Finally, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management acquired a new position in VanEck Pharmaceutical ETF in the 3rd quarter worth $8,743,000.

VanEck Pharmaceutical ETF Stock Performance

Shares of NASDAQ PPH opened at $90.19 on Friday. VanEck Pharmaceutical ETF has a 1 year low of $77.70 and a 1 year high of $99.51. The stock’s 50-day simple moving average is $91.52 and its 200-day simple moving average is $93.00. The firm has a market cap of $666.50 million, a price-to-earnings ratio of 21.04 and a beta of 0.72.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.